Abstract
Objective – a description of clinical cases of impulsivecompulsive disorders in Parkinson , s disease. The first clinical case. Patient N. , 75 years old, suffering for 15 years from Parkinson , s disease, akineticrigid form of the disease, stage 4 by Hyun–Yar. Since 2009, he received levodopa/carbidopa 250/25 mg 5 times/day (daily dose of 1250 mg of levodopa); pramipexole 3.5 mg per day (daily dose 3.5 mg), amantadine sulfate 100 mg 5 times/day (daily dose 500 mg). While taking antiparkinsonian drugs the patient developed behavioral disorders such as dopamine disregulatory syndrome combined with punding, hypersexuality and compulsive shopping accompanied by visual hallucinations. The total equivalent dose of levodopa was 1600 mg per day. The second clinical case. Patient R. , 52 years old, suffers from Parkinson , s disease about 5 years, a mixed form. She complained of slowness of movement, tremor in her left hand, sleep disturbances, poor mood. The clinic was appointed piribedil 50 mg 3 times per day. Despite the fact that the patient took only one of dopaminergic drugs in a therapeutic daily dose, she developed impulsivecompulsive disorder as hyper sexuality, compulsive shopping and binge eating. Results. In the first clinical case for correction of behavioral disorders in patients with Parkinson , s disease levodopa/carbidopa dose was reduced to 750 mg per day (3/4 Tab. 4 times a day); added to levodopa/benserazide dispersible 100 mg morning and levodopa/benserazide 100 mg before sleep (total dose of levodopa of 950 mg per day). Amantadine sulfate and pramipexole were canceled. It was added to the therapy of atypical neuroleptic clozapine dose 6,25 mg overnight. After 3 months marked improvement, regressed visual hallucina tions, improved family relationships, background mood became more stable. The patient continue to sing karaoke, but this hobby has be come less intrusive. In the second clinical event correction impulsivecompulsive disorders piribedil was replaced with pramipexole 1.5 mg prolonged form one time a day. At the control examination after 3 months behavioral disorders completely regressed. Conclusion. This article describes two clinical cases of impulsivecompulsive disorders in patients with Parkinson s disease, methods of di agnosis and correction capabilities of these disorders.
Highlights
Ключевые слова: импульсивно-компульсивные расстройства, поведенческие расстройства, нарушение импульсного контроля, болезнь Паркинсона, дофаминергические препараты, дофаминовый дизрегуляционный синдром, пандинг, гиперсексуальность, компульсивное переедание, компульсивный шопинг, игромания, леводопа, эквивалентная доза леводопы, агонисты дофаминовых рецепторов
While taking antiparkinsonian drugs the patient developed behavioral disorders such as dopamine disregulatory syndrome combined with punding, hypersexuality and compulsive shopping aTchceosmecpoanndiecdlibnyicvailsucaasleh.aPlaluticeinntaRtio.,n5s.2Tyheeartsotoaldl e, qsuufifvearlsefnrtodmosPeaorkf ilnevsoond,ospdaisweaasse16a0b0oumt g5 per day. years, a mixed form. She complained of slowness of movement, tremor in her left hand, sleep disturbances, poor mood
It was added to the therapy of atypical neuroleptic clozapine dose 6,25 mg overnight
Summary
Ключевые слова: импульсивно-компульсивные расстройства, поведенческие расстройства, нарушение импульсного контроля, болезнь Паркинсона, дофаминергические препараты, дофаминовый дизрегуляционный синдром, пандинг, гиперсексуальность, компульсивное переедание, компульсивный шопинг, игромания, леводопа, эквивалентная доза леводопы, агонисты дофаминовых рецепторов. DOI: 10.17 650/1818-8338-2015-9-3-52-56 IMPULSIVE-COMPULSIVE DISORDERS IN PARKINSON,S DISEASE. In the first clinical case for correction of behavioral disorders in patients with Parkinson,s disease levodopa/carbidopa dose was reduced to 750 mg per day (3/4 Tab. 4 times a day); added to levodopa/benserazide dispersible 100 mg morning and levodopa/benserazide In the second clinical event correction impulsive-compulsive disorders piribedil was replaced with pramipexole 1.5 mg prolonged form one time a day.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.